

## An Extension Study to Provide Continued Bevacizumab Therapy to Participants With Solid Tumors Who Were Previously Enrolled in a Roche/Genentech Sponsored Study

**Trial Status**  
Completed

**Trial Runs In**  
21 Countries

**Trial Identifier**  
NCT01588184 2011-002009-31  
MO25757

---

*The information is taken directly from public registry websites such as ClinicalTrials.gov, EuClinicalTrials.eu, ISRCTN.com, etc., and has not been edited.*

### Official Title:

A Single Arm, Open Label Multicentre Extension Study of Bevacizumab in Patients With Solid Tumours on Study Treatment With Bevacizumab, at the End of A F. Hoffmann-La Roche and/or Genentech Sponsored Study

### Trial Summary:

This single-arm, open-label, multicenter extension study will provide continued bevacizumab therapy to participants with solid tumors who were previously enrolled in a Roche/Genentech sponsored study and who derived benefit from the bevacizumab therapy. Participants will receive the same dose and regimen of bevacizumab as used in the previous parent trial and continue this treatment until progression of disease or unacceptable toxicity, withdrawal of consent or death whichever occurs first.

**Hoffmann-La Roche**  
Sponsor

**Phase 4**  
Phase

---

**NCT01588184 2011-002009-31 MO25757**  
Trial Identifiers

---

### Eligibility Criteria:

**Gender**  
All

**Age**  
#18 Years

**Healthy Volunteers**  
No

---

### Inclusion Criteria:

# ForPatients

*by Roche*

- Participant is treated with bevacizumab at the end of the Roche/Genentech sponsored parent trial and continues to have benefit as judged by the investigator
- Eligible for continuation of bevacizumab treatment at the end of a parent trial, according to parent trial protocol
- Able to comply with this extension study protocol (MO25757)

## ***Exclusion Criteria:***

- Evidence of disease progression assessed according to parent trial protocol during the screening phase for this extension study
- Evidence of any adverse event potentially attributable to bevacizumab, for which the local label recommends permanent discontinuation
- A treatment interruption with bevacizumab of more than 42 days since the last administration of bevacizumab in the parent trial
- Evidence of any other disease that would put the participant at high risk for treatment-related complications